Trials / Terminated
TerminatedNCT06297642
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
A Phase Ib Clinical Trial of TQB2928 Injection Combined With Penpulimab in the Treatment of Patients With Advanced Malignant Tumors.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2928 injection | Anti-CD47 monoclonal antibody |
| DRUG | Penpulimab | Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1) |
Timeline
- Start date
- 2024-05-24
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
- First posted
- 2024-03-07
- Last updated
- 2024-08-06
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06297642. Inclusion in this directory is not an endorsement.